Login / Signup

Anti-EGFR Antibody-Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth.

Anthony CheungAlicia M ChenowethAnnelie JohanssonRoman LaddachNaomi Jayne GuppyJennifer TrendellBenjamina EsapaAntranik MavousianBlanca Navarro-LlinasSyed HaiderPablo Romero-ClavijoRicarda M HoffmannPaolo AndriolloKhondaker Miraz RahmanPaul JacksonSophia TsokaSheeba IrshadIoannis RoxanisAnita GrigoriadisDavid E ThurstonChristopher J LordAndrew N J TuttSophia N Karagiannis
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Exploiting EGFR overexpression, and dysregulated cell cycle in aggressive and treatment-refractory tumors, a cetuximab-CDK inhibitor ADC may provide selective and efficacious delivery of cell cycle-targeted agents to basal-like/TNBCs, including chemotherapy-resistant residual disease.
Keyphrases
  • cell cycle
  • cell proliferation
  • small cell lung cancer
  • cancer therapy
  • epidermal growth factor receptor
  • tyrosine kinase
  • locally advanced
  • drug delivery
  • transcription factor
  • magnetic resonance
  • rectal cancer
  • wild type